Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

METHYLOMIC DNA methylation markers to predict treatment success of biologicals in Crohn’s disease.

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€9.4m
Total cost
€9.4m
Partners
18 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101095449

What the project is doing

In the project's own words, from its summary on CORDIS.

Monoclonal antibodies have become a mainstay of therapy in common immune-mediated diseases (IMID) including Crohn’s disease (CD), rheumatoid arthritis (RA), and psoriasis (PsO). Current therapeutics include antibodies (“biologicals”) targeting inflammatory proteins such as Tumor Necrosis Factor (adalimumab), leukocyte trafficking (vedolizumab), or IL-12/IL-23 (ustekinumab). At present however, it cannot be predicted which biological will be effective in an individual patient, with only <40% of patients showing primary response to any given therapeutic.

Treatment failure is associated with disease complications, and increased health care costs.. Hence the overwhelming need for predictive biomarkers to guide personalised medicine in IMID is evident. No biomarker to target therapy is validated in clinical practice. In METHYLOMIC, we build on multiple previous cohort studies in which we confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD.

Specifically, we discovered and validated differential DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for 3 approved biologicals in CD. Through the use of machine learning algorithms, treatment response could be predicted with up to 93% accuracy for each biological for CD, and RA. METHYLOMICS is committed to bringing personalised treatment-selection in CD and other IMID to clinical practice.

We have teamed up clinical, epigenetic, and DNA diagnostics experts, patient organisations, and companies across Europe, for further validation studies, develop a marketable rapid targeted methylation assay that we than validate in a unique prospective randomised clinical trial for CD. Efficiency and cost-effectiveness is assessed in great detail and regulatory approval is guided by experts to assure delivery of the first epigenetic kit personalised treatment of CD.

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
Belgian Ibd Research and DevelopmentZaventemBelgiumParticipant
DiagenodeSeraingBelgiumAssociatedpartner
International Federation of Crohn's and Ulcerative Colitis AssociationsBruxelles / BrusselBelgiumParticipant
Universiteit GentGentBelgiumParticipant
Asphalion SLBarcelonaSpainParticipant
Szegedi TudomanyegyetemSzegedHungaryParticipant
Universita Vita-Salute San RaffaeleMilanoItalyParticipant
Alimentiv BVAmsterdamNetherlandsParticipant
Descin BVVinkeveenNetherlandsParticipant
Genome Diagnostics B.vUtrechtNetherlandsParticipant
Horaizon Technology B.v.DelfgauwNetherlandsParticipant
Stichting VuAmsterdamNetherlandsParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
Univerzitetni Klinicni Center LjubljanaLjubljanaSloveniaParticipant
King's College LondonLondonUnited KingdomAssociatedpartner
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner
Twist Bioscience CoorporationSouth San FranciscoUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI